Boxhorn H K, Eck S L
Department of Medicine, University of Pennsylvania Medical Center, Philadelphia, USA.
Hematol Oncol Clin North Am. 1998 Jun;12(3):665-75. doi: 10.1016/s0889-8588(05)70014-9.
Gene therapy for breast cancer is still in the very early stages of development. Many of the molecular strategies that have been proposed are also being developed for other cancers. Their application to breast cancer, however, needs to address several issues specific to this disease such as the widespread nature of metastases, the indolent growth of the tumor cells, and the production by the tumor of immunosuppressive agents. Nonetheless, these approaches appear promising, particularly those that employ a combination of strategies. Gene therapies that affect the biology of breast cancer cells or regulate host immune mechanisms have been most successful and may be paired with existing therapies for breast cancer.
乳腺癌的基因治疗仍处于非常早期的发展阶段。许多已提出的分子策略也正在针对其他癌症进行研发。然而，将它们应用于乳腺癌时，需要解决一些该疾病特有的问题，比如转移的广泛性、肿瘤细胞的惰性生长以及肿瘤产生免疫抑制因子等问题。尽管如此，这些方法似乎很有前景，尤其是那些采用联合策略的方法。影响乳腺癌细胞生物学特性或调节宿主免疫机制的基因治疗最为成功，并且可以与现有的乳腺癌治疗方法相结合。
